Glutamic Acid

Glutamic Acid

SCHEMBL3126271

N[C@@H](CCC(=O)O)C(=O)O.Nc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM8 O00222 7/20 0.53
▸ GRM4 Q14833 7/20 0.53
▸ GRM6 O15303 3/20 0.53
▸ GRIK1 P39086 2/20 0.53
▸ GRIK2 Q13002 2/20 0.53
▸ GRIN2D O15399 1/20 0.53
▸ GRIN3B O60391 1/20 0.53
▸ GSR P00390 1/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ GRM5 P41594 1/20 0.53
▸ GRIA1 P42261 1/20 0.53
▸ GRIA2 P42262 1/20 0.53
▸ GRIA3 P42263 1/20 0.53
▸ SLC1A3 P43003 1/20 0.53
▸ SLC1A2 P43004 1/20 0.53
▸ SLC1A1 P43005 1/20 0.53
▸ GRIA4 P48058 1/20 0.53
▸ GRIN1 Q05586 1/20 0.53
▸ GRIN2A Q12879 1/20 0.53
▸ GRIK3 Q13003 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamic Acid SCHEMBL29088693 0.99 GRM8 (0.51) GRM8GRM4GRM6GRIK1GRIK2
D-Glutamate SCHEMBL28889377 0.85 GRM8 (0.49) GRM8GRM4GRM6GRIK1GRIK2
Lysine SCHEMBL28327845 0.83 GSR (0.56) GRM8GRM4GRM6GRIK1GRIK2
Lysine SCHEMBL28385610 0.83 GSR (0.56) GRM8GRM4GRM6GRIK1GRIK2
4-Nitroaniline SCHEMBL2934316 0.82 ALDH1A1 (0.56) GRM8GRM4GRM6GRIK1GRIK2
4-Nitroaniline SCHEMBL2934312 0.82 ALDH1A1 (0.56) GRM8GRM4GRM6GRIK1GRIK2
4-Nitroaniline SCHEMBL6705231 0.82 GRM8 (0.49) GRM8GRM4GRM6GRIK1GRIK2
4-Nitroaniline SCHEMBL10381907 0.82 GRM8 (0.49) GRM8GRM4GRM6GRIK1GRIK2
Lysine SCHEMBL27760108 0.82 GSR (0.54) GRM8GRM4GRM6GRIK1GRIK2
Lysine SCHEMBL27760106 0.82 GSR (0.54) GRM8GRM4GRM6GRIK1GRIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-9196912-A — — None — — JP disclosed
CN-119320427-A Stropharia rugoso-annulata umami peptide and screening method and application thereof 华东师范大学 2025-01-17 — — CN disclosed
CN-112961848-B Novel aminopeptidase and soluble expression method thereof 中国海洋大学 2022-09-09 — — CN disclosed
US-20100197745-A1 GAMMA-GLUTAMYL TRANSPEPTIDASE INHIBITORS AND METHODS OF USE THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA 2010-08-05 — — US disclosed
JP-H09196912-A ALZHEIMER'S DISEASE DIAGNOSTIC DRUG TOKYO MET GOV RINSHIYOU IGAKU SOGO KENKYUSHO 1997-07-31 — — JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197745-A1 GAMMA-GLUTAMYL TRANSPEPTIDASE INHIBITORS AND METHODS OF USE GGT1, GSTA1, GLS GRM8 3917/4885GRM4 3252/4885GRM6 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback